Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.

Tumor Microenvironment Receptors, IgG T-Lymphocytes, Regulatory Immunity, Innate Interferon Type I

Journal

Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119

Informations de publication

Date de publication:
11 2022
Historique:
received: 11 10 2021
accepted: 20 09 2022
pubmed: 28 10 2022
medline: 30 11 2022
entrez: 27 10 2022
Statut: ppublish

Résumé

Despite the clinical success of checkpoint inhibitors, a substantial gap still exists in our understanding of their mechanism of action. While antibodies to cytotoxic T lymphocyte-associated protein-4 (CTLA-4) were developed to block inhibitory signals in T cells, several recent studies have demonstrated that Fcγ receptor (FcγR)-dependent depletion of regulatory T cells (T

Identifiants

DOI: 10.1038/s43018-022-00447-1 PMID: 36302895
pubmed: 36302895
doi: 10.1038/s43018-022-00447-1
pii: 10.1038/s43018-022-00447-1
doi:

Substances chimiques

Receptors, IgG 0
Interferon Type I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1336-1350

Subventions

Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : Cancer Research UK
ID : C36463/A22246
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C36463/A20764
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C416/A18088
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C33499/A20265
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).
pubmed: 33811120 doi: 10.1158/2159-8290.CD-20-1680
Weiss, S. A., Wolchok, J. D. & Sznol, M. Immunotherapy of melanoma: facts and hopes. Clin. Cancer Res. 25, 5191–5201 (2019).
pubmed: 30923036 pmcid: 6726509 doi: 10.1158/1078-0432.CCR-18-1550
Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17–35 (2020).
pubmed: 31940268 doi: 10.1016/j.immuni.2019.12.011
Walker, L. S. K. & Sansom, D. M. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 36, 63–70 (2015).
pubmed: 25582039 pmcid: 4323153 doi: 10.1016/j.it.2014.12.001
Walker, L. S. K. T
pubmed: 23849743 pmcid: 3989116 doi: 10.1016/j.jaut.2013.06.006
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
pubmed: 8596936 doi: 10.1126/science.271.5256.1734
Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695–1710 (2013).
pubmed: 23897981 pmcid: 3754863 doi: 10.1084/jem.20130579
Arce Vargas, F. et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33, 649–663 (2018).
pubmed: 29576375 pmcid: 5904288 doi: 10.1016/j.ccell.2018.02.010
Bulliard, Y. et al. Activating Fcγ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685–1693 (2013).
pubmed: 23897982 pmcid: 3754864 doi: 10.1084/jem.20130573
Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32–42 (2013).
pubmed: 24777248 doi: 10.1158/2326-6066.CIR-13-0013
Quezada, S. A. & Peggs, K. S. Lost in translation: deciphering the mechanism of action of anti-human CTLA-4. Clin. Cancer Res. 25, 1130–1132 (2019).
pubmed: 30291135 doi: 10.1158/1078-0432.CCR-18-2509
Yofe, I., Dahan, R. & Amit, I. Single-cell genomic approaches for developing the next generation of immunotherapies. Nat. Med. 26, 171–177 (2020).
pubmed: 32015555 doi: 10.1038/s41591-019-0736-4
Giladi, A. & Amit, I. Single-cell genomics: a stepping stone for future immunology discoveries. Cell 172, 14–21 (2018).
pubmed: 29328909 doi: 10.1016/j.cell.2017.11.011
Mulder, K. et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54, 1883–1900 (2021).
pubmed: 34331874 doi: 10.1016/j.immuni.2021.07.007
Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775–789 (2019).
pubmed: 30595452 doi: 10.1016/j.cell.2018.11.043
Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867–1876 (2018).
pubmed: 30523328 doi: 10.1038/s41591-018-0269-2
Cohen, Y. C. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat. Med. 27, 491–503 (2021).
pubmed: 33619369 pmcid: 7612793 doi: 10.1038/s41591-021-01232-w
Katzenelenbogen, Y. et al. Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell 182, 872–885 (2020).
pubmed: 32783915 doi: 10.1016/j.cell.2020.06.032
Giladi, A. et al. Dissecting cellular crosstalk by sequencing physically interacting cells. Nat. Biotechnol. 38, 629–637 (2020).
pubmed: 32152598 doi: 10.1038/s41587-020-0442-2
Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).
pubmed: 18064051 doi: 10.1038/nri2206
Jeong, H. J. et al. Myeloid-derived suppressor cells mediate inflammation resolution in humans and mice with autoimmune uveoretinitis. J. Immunol. 200, 1306–1315 (2018).
pubmed: 29311360 doi: 10.4049/jimmunol.1700617
Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485–498 (2021).
pubmed: 33526920 pmcid: 7849958 doi: 10.1038/s41577-020-00490-y
Mehta, A. K., Kadel, S., Townsend, M. G., Oliwa, M. & Guerriero, J. L. Macrophage biology and mechanisms of immune suppression in breast cancer. Front. Immunol. 12, 643771 (2021).
pubmed: 33968034 pmcid: 8102870 doi: 10.3389/fimmu.2021.643771
Shao, X. et al. CellTalkDB: a manually curated database of ligand–receptor interactions in humans and mice. Brief. Bioinform. 22, bbaa269 (2021).
pubmed: 33147626 doi: 10.1093/bib/bbaa269
Molgora, M. et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 182, 886–900 (2020).
pubmed: 32783918 pmcid: 7485282 doi: 10.1016/j.cell.2020.07.013
Deczkowska, A., Weiner, A. & Amit, I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell 181, 1207–1217 (2020).
pubmed: 32531244 doi: 10.1016/j.cell.2020.05.003
Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559–572 (2017).
pubmed: 28555670 pmcid: 5731833 doi: 10.1038/nri.2017.49
Clark, N. M. et al. Regulatory T cells support breast cancer progression by opposing IFN-γ-dependent functional reprogramming of myeloid cells. Cell Rep. 33, 108482 (2020).
pubmed: 33296659 pmcid: 7811278 doi: 10.1016/j.celrep.2020.108482
Kim, J. M., Rasmussen, J. P. & Rudensky, A. Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191–197 (2007).
pubmed: 17136045 doi: 10.1038/ni1428
Dhodapkar, K. M. et al. Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J. Exp. Med. 204, 1359–1369 (2007).
pubmed: 17502666 pmcid: 2118610 doi: 10.1084/jem.20062545
Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017).
pubmed: 29033130 pmcid: 5685550 doi: 10.1016/j.cell.2017.09.028
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
pubmed: 25409260 pmcid: 4315319 doi: 10.1056/NEJMoa1406498
Dolgin, E. Antibody engineers seek optimal drug targeting TIGIT checkpoint. Nat. Biotechnol. 38, 1007–1009 (2020).
pubmed: 32887966 doi: 10.1038/s41587-020-0666-1
Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
pubmed: 25428507 pmcid: 4279952 doi: 10.1038/nature13988
Romano, E. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl Acad. Sci. USA 112, 6140–6145 (2015).
pubmed: 25918390 pmcid: 4434760 doi: 10.1073/pnas.1417320112
Mujal, A. M. et al. Holistic characterization of tumor monocyte-to-macrophage differentiation integrates distinct immune phenotypes in kidney cancer. Cancer Immunol. Res. 10, 403–419 (2022).
pubmed: 35181780 pmcid: 8982148 doi: 10.1158/2326-6066.CIR-21-0588
Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3
pubmed: 30054281 doi: 10.1158/1078-0432.CCR-18-0762
Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl Acad. Sci. USA 109, 6181–6186 (2012).
pubmed: 22474370 pmcid: 3341029 doi: 10.1073/pnas.1203954109
Prinz, M. et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28, 675–686 (2008).
pubmed: 18424188 doi: 10.1016/j.immuni.2008.03.011
Deczkowska, A. et al. XCR1
pubmed: 34017133 doi: 10.1038/s41591-021-01344-3
Karlsson, F., Robinson-Jackson, S. A., Gray, L., Zhang, S. & Grisham, M. B. Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis. Methods Mol. Biol. 677, 47–61 (2011).
pubmed: 20941602 pmcid: 3062849 doi: 10.1007/978-1-60761-869-0_4
Keren-Shaul, H. et al. MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing. Nat. Protoc. 14, 1841–1862 (2019).
pubmed: 31101904 doi: 10.1038/s41596-019-0164-4
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902 (2019).
pubmed: 31178118 pmcid: 6687398 doi: 10.1016/j.cell.2019.05.031
Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 1–15 (2019).
doi: 10.1186/s13059-019-1874-1
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
pubmed: 29608179 pmcid: 6700744 doi: 10.1038/nbt.4096
Wilkerson, D. M. & Hayes, N. D. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinform. 26, 1572–1573 (2010).
doi: 10.1093/bioinformatics/btq170
Korotkevich, G., Sukhov, V. & Sergushichev, A. (2019). Fast gene set enrichment analysis. bioRxiv. http://biorxiv.org/content/early/2016/06/20/060012
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinform. 27, 1739–1740 (2011).
doi: 10.1093/bioinformatics/btr260

Auteurs

Ido Yofe (I)

Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.

Tomer Landsberger (T)

Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.

Adam Yalin (A)

Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.

Isabelle Solomon (I)

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Cristobal Costoya (C)

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Dafne Franz Demane (DF)

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Mansi Shah (M)

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Eyal David (E)

Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.

Chamutal Borenstein (C)

Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.

Oren Barboy (O)

Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.

Ignacio Matos (I)

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Karl S Peggs (KS)

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.

Sergio A Quezada (SA)

Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.
ORCID: 0000-0002-9763-1700

Ido Amit (I)

Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. ido.amit@weizmann.ac.il.
ORCID: 0000-0003-2968-877X

Articles similaires

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Megan Cole, Panayiotis Anastasiou, Claudia Lee et al.
1.00
T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease.

Adrian Gervais, Paul Bastard, Lucy Bizien et al.
1.00
Humans Interferon Type I Ross River virus Encephalitis, Tick-Borne Antibodies, Neutralizing

Decorin-armed oncolytic adenovirus promotes natural killers (NKs) activation and infiltration to enhance NK therapy in CRC model.

Xue Li, Yuning Zhang, Zhuang Mao et al.
1.00
Killer Cells, Natural Animals Colorectal Neoplasms Decorin Adenoviridae

Revealing molecular mechanisms of early-onset tongue cancer by spatial transcriptomics.

Marina R Patysheva, Elena S Kolegova, Anna A Khozyainova et al.
1.00
Humans Tongue Neoplasms Male Adult Middle Aged

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Anti-CTLA-4 antibodies drive myeloid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteur Fc › Récepteurs du fragment Fc des IgG › Anti-CTLA-4 antibodies drive myeloid...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T régulateurs › Anti-CTLA-4 antibodies drive myeloid...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité innée › Anti-CTLA-4 antibodies drive myeloid...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Anti-CTLA-4 antibodies drive myeloid...